Evidence map›Paper›PMID 33568129›Full record

ArticleThrombosis journal2021

A cross-sectional, multicenter, observational study to assess the prophylaxis of venous thromboembolism in Lebanese and Jordanian hospitals.

Imad Hajj, Mahmoud Al-Masri, Kaldoun Bashaireh, Mohammed Bani Hani, Shadi Hamouri, Joe Khouzami, Nisrine Sabra, Chahine Fadel

Open access · goldAbstract read
In one paragraph

Article in Thrombosis journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Imad HajjDepartment of Surgery, Saint George Hospital University Medical Center, Ashrafiyeh, Beirut, Lebanon. iphajj@stgeorgehospital.org.ORCID http://orcid.org/0000-0002-8324-0960
Mahmoud Al-MasriDepartment of Surgery, King Hussein Cancer Center, PO Box 1269, Al-Jubeiha, Amman, 11941, Jordan. malmasri@khcc.jo.
Kaldoun BashairehDepartment of Special Surgery, Faculty of Medicine, Jordan University of Science and Technology, Ar-Ramtha, Jordan.
Mohammed Bani HaniDepartment of General Surgery and Urology, Faculty of Medicine, Jordan University of Science and Technology, King Abdallah University Hospital, Ar-Ramtha, Jordan.
Shadi HamouriDepartment of General Surgery and Urology, Faculty of Medicine, Jordan University of Science and Technology, King Abdallah University Hospital, Ar-Ramtha, Jordan.
Joe KhouzamiSanofi, Beirut, Lebanon.
Nisrine SabraSanofi, Beirut, Lebanon.
Chahine FadelSanofi, Beirut, Lebanon.
Jordan University of Science and Technology · JOOrient-Institut Beirut · LBKing Hussein Cancer Center · JOSaint George Hospital · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a growing body of evidence showing substantial underuse of appropriate venous thromboembolism (VTE) prophylaxis in patients at risk. In the present study, our goal was to assess the current practices in the use rate of VTE prophylaxis among hospitalized patients in Jordan and Lebanon.

methodsA cross-sectional, multicenter, observational study was conducted on 40 centers across Lebanon and Jordan. We included patients who were admitted to the participating hospitals for the treatment of a serious medical or surgical illness. The patients' records were screened for the fulfillment of inclusion/exclusion criteria during a single assessment visit. The proportion of medical and surgical patients who were at risk of VTE and the thrombo-prophylactic measures employed by physicians for these patients were assessed according to the American College of Chest Physicians (ACCP 2016) guidelines.

resultsThe present study included 704 patients (400 from Jordan and 304 from Lebanon) with a mean age of 54.9 ± 17.5 years. Almost 59% of the patients received prophylaxis treatment in form of pharmacological anticoagulant prophylaxis and/or mechanical prophylaxis. Low molecular weight heparin was the most commonly used anticoagulant for VTE prophylaxis in 366 out of the total 704 (51.9%) patients in the analysis cohort. Two hundred and sixteen patients (52, 95% confidence interval [47.1-56.9%]) received appropriate prophylactic agents out of 415 patients who were eligible for prophylaxis according to the ACCP 2016 guidelines. On the other hand, 199 (72.1, 95% confidence interval [66.4-77.3%) patients received prophylaxis out of 276 ineligible patients. The rate of compliance to guidelines showed wide variations according to the type of hospital, specialty, and the patients' age. The multivariate logistic regression analysis showed that only age was a significant predictor of appropriate VTE prophylaxis (odds ratio [OR] 1.05, P < 0.001).

conclusionThe rates of the appropriate use of VTE prophylaxis are low in Lebanon and Jordan. There is a lack of compliance to guidelines for VTE prophylaxis use for hospitalized patients in both countries.

Indexed as

ACCP guidelineVenous thromboembolismVTE prophylaxis

Identifiers

PMID33568129
PMCPMC7877011
OpenAlexW3108541688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.